• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Deficiency Diseases

Deficiency Diseases - 33 Studies Found

Completed : IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency
:
  • T-Cell Immune Deficiency Diseases
  • Severe Combined Immunodeficie
    : 2005-09-27
    : Drug: Busulfan, Fludarabine and ATG
Completed : International Collaborative Gaucher Group (ICGG) Gaucher Registry
:
  • Gaucher Disease
  • Cerebroside Lipidosis Syndrome
  • Glucocerebr
    : 2006-07-12
Completed : A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.
:
  • Gaucher Disease Type I
  • Cerebroside Lipidosis Syndrome
  • Cluc
    : 2006-08-15
    : Drug: Cerezyme (imiglucerase for injection)
Completed : Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
:
  • Gaucher Disease, Type 1
  • Cerebroside Lipidosis Syndrome
  • Glu
    : 2006-08-15
    : Drug: Cerezyme Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
Completed : A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
:
  • Gaucher Disease, Type 1
  • Cerebroside Lipidosis Syndrome
  • Glu
    : 2006-07-27
    : Drug: Eliglustat tartrate Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat
Active, not recruiting : Growth and Development Study of Alglucosidase Alfa.
:
  • Pompe Disease
  • Glycogen Storage Disease Type II (GSD-II)
  • Ac
    : 2007-06-13
    : Biological: alglucosidase alfa Intravenous (IV) infusion: 20mg/kg every 2 weeks
Approved for marketing : Alglucosidase Alfa Temporary Access Program
:
  • Glycogen Storage Disease Type II (GSD-II)
  • Pompe Disease (Late-Onset)
  • Pompe Disease (Late-onset)
  • Glycogen Storage Disease Type II (GSD-II)
  • Pompe Disease (Late-onset)
  • Glycogen Storage Disease Type II (GSD-II)
  • Pompe Disease (Late-onset)
  • Glycogen Storage Disease Type II (GSD-II)
  • Biological: alglucosidase alfa

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.